SELECT Trials Groundbreaking Results In 2023, in a landmark finding, the SELECT trial showed that adults with overweight or obesity but without diabetes, who had previously experienced a heart attack, stroke and/or had peripheral artery disease, taking semaglutide had a 20% reduction in major adverse cardiac events such as heart attacks and strokes compared to those on placebo over the course of 3 years
Semaglutide is primarily metabolized through proteolytic degradation, the breakdown of peptide bonds by enzymes
These studies have only examined one form of reduced folate, folinic acid, and have only examined treatment response in limited studies
They feel empowered that they can finally control their weight
The most important safety consideration is sourcing: peptides from unregulated "research" suppliers carry unknown contamination and quality risks
It helps keep blood sugar levels in check, which is crucial for diabetes management
